The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 407.70
Bid: 406.40
Ask: 406.60
Change: 6.70 (1.67%)
Spread: 0.20 (0.049%)
Open: 408.90
High: 409.60
Low: 404.30
Prev. Close: 401.00
RTO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q4 2020 Acquisitions and Trading Update

8 Jan 2021 07:00

RNS Number : 0002L
Rentokil Initial PLC
08 January 2021
 

 

8 January 2021

Rentokil Initial plc - Q4 2020 Acquisitions and Trading Update

A very strong end to the year for M&A in our key North America pest control market with continued strong trading boosted by momentum in disinfection services

Rentokil Initial plc (FTSE: RTO, "the Company") announces today the acquisition of Environmental Pest Service ('EPS'), a full-service, commercial and residential pest control company based in Tampa, Florida.

EPS was ranked 15th in the PCT Magazine 2020 Top 100 listing of leading US pest control companies and generated annualised revenues of c.$82m (£60m) in 2020. EPS employs c.640 people (of which 386 are in service roles) in 30 branches across four separate regions: East Florida; West Florida; North Georgia; and North Carolina. It has two brand names, Arrow Environmental and Bug Out.

In addition to the acquisition of EPS, we have acquired a further eight high quality pest control companies in North America in Q4, with combined annualised revenues of c.$62m (c.£48m) in 2020.

Total acquisitions in 2020

For the full year ended 31 December 2020, we have acquired 23 new businesses, with annualised revenues of over £150m, for a cash spend of c.£180m (of which c.£150m was in H2). This excludes the consideration for EPS which was paid at the beginning of January 2021.

Announcement of Preliminary Results and Updated Guidance for 2020

Rentokil Initial plc will announce its 2020 Preliminary results on Thursday, 4 March. In our Q3 Trading Statement last October, we indicated that despite continued uncertainty across our business as a result of the ongoing pandemic, we were hopeful of being able to maintain the momentum we had seen in Q3 into the fourth quarter which would result in an outcome for the full year at least in line with expectations. Trading across both our Hygiene and Pest Control categories has continued to be strong in Q4 - primarily reflecting continued strong sales from one-off disinfection services - and we now expect the final outcome for the year to be slightly above the top end of the range of current market expectations for Adjusted PBTA*.

We are looking to the future with confidence. However, while global vaccination programmes offer hope that we will see an end to the pandemic, the financial outlook for 2021 inevitably remains uncertain, in particular with limited visibility on the sustainability of one-off disinfection services, the recent strengthening of sterling, and the undetermined impacts arising from recently rising cases of COVID-19 globally and new and prolonged country lockdowns. We look forward to providing a further update with our full year results on 4 March.

Andy Ransom, Chief Executive of Rentokil Initial plc, said:

"Despite the impact of COVID-19 on our business in 2020, we have exited the year in a strong position, with the trading momentum of Q3 continuing throughout Q4 and with an excellent overall delivery of M&A, which significantly accelerated as the year drew to a close. We have gained approximately 2000 new colleagues from acquisitions in 2020, and I am delighted to welcome them all to Rentokil Initial.

"I am also very pleased to announce our acquisition of Environmental Pest Service. EPS is a high-quality company of significant scale with a strong reputation for service delivery and technical ability, and with a culture which will make an excellent fit with our own. This acquisition is very much in line with our strategy to acquire pest control businesses that build customer density and add to our scale in key local markets - by acquiring EPS we can immediately add density, provide improved customer service, and provide incremental revenue to several of our sub-scale existing Rentokil locations on the Florida Gulf Coast, as well as build on our existing presence in north eastern Florida, metro Atlanta and North Carolina."

Investor / Analyst enquiries:

Katharine Rycroft, Investor Relations

Rentokil Initial plc

07811 270 734

Media enquiries:

Malcolm Padley, Corporate Communications

Rentokil Initial plc

07788 978 199

 

* Our Company-compiled current range of analyst forecasts for Adjusted PBTA for 2020 is £292m to £337m.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQEAAFXESLFEAA
Date   Source Headline
15th Feb 20195:15 pmRNSHolding(s) in Company
1st Feb 20197:00 amRNSChange to Director's details
4th Dec 20187:00 amRNSDefined benefit pension scheme buy-in with PIC
20th Nov 20185:17 pmRNSHolding(s) in Company
16th Nov 20184:14 pmRNSHolding(s) in Company
24th Oct 20182:36 pmRNSDirector/PDMR Shareholding
18th Oct 20187:00 amRNSQ3 Trading Update
2nd Oct 201812:17 pmRNSBlock listing Interim Review
25th Sep 20187:25 amRNSDirector Declaration
13th Sep 20184:43 pmRNSDirector/PDMR Shareholding
29th Aug 20187:00 amRNSDirector/PDMR Shareholding
20th Aug 201812:44 pmRNSDirector/PDMR Shareholding
1st Aug 20183:12 pmRNSHolding(s) in Company
31st Jul 20187:00 amRNSInterim Results
27th Jul 20185:07 pmRNSHolding(s) in Company
5th Jul 20184:52 pmRNSHolding(s) in Company
5th Jul 201811:36 amRNSDirector Declaration
28th Jun 20184:10 pmRNSHolding(s) in Company
7th Jun 20185:16 pmRNSDirector Declaration
17th May 20184:12 pmRNSDirector/PDMR Shareholding
16th May 20187:00 amRNSNotice of Capital Markets Days
9th May 20185:40 pmRNSResult of AGM
4th May 20184:27 pmRNSDirector/PDMR Shareholding
2nd May 201810:52 amRNSDirector/PDMR Shareholding
1st May 20186:00 pmRNSDirector/PDMR Shareholding
30th Apr 20185:48 pmRNSDirector/PDMR Shareholding
26th Apr 20183:24 pmRNSHolding(s) in Company
25th Apr 20184:50 pmRNSHolding(s) in Company
24th Apr 20183:55 pmRNSHolding(s) in Company
24th Apr 201810:53 amRNSHolding(s) in Company
20th Apr 20184:09 pmRNSDirector/PDMR Shareholding
19th Apr 20184:32 pmRNSHolding(s) in Company
19th Apr 20187:00 amRNSQ1 Trading Update
5th Apr 201812:57 pmRNSHolding(s) in Company
5th Apr 201811:06 amRNSAnnual Financial Report
4th Apr 20186:01 pmRNSDirector/PDMR Shareholding
3rd Apr 20184:12 pmRNSBlock listing Interim Review
29th Mar 201811:55 amRNSTotal Voting Rights
27th Mar 20184:01 pmRNSHolding(s) in Company
27th Mar 201812:58 pmRNSAdditional Listing
8th Mar 20185:50 pmRNSDirector/PDMR Shareholding
1st Mar 20187:00 amRNSFinal Results
27th Dec 20177:00 amRNSDirector/PDMR Shareholding
20th Dec 20173:40 pmRNSDirector/PDMR Shareholding
22nd Nov 20174:30 pmRNSHolding(s) in Company
17th Nov 20177:00 amRNSIssue of new EUR400m bond
13th Nov 20174:35 pmRNSHolding(s) in Company
13th Nov 20177:00 amRNSPurchase of Vector Disease Acquisition LLC
7th Nov 20174:14 pmRNSHolding(s) in Company
6th Nov 20177:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.